1. Home
  2. OSPN vs ALT Comparison

OSPN vs ALT Comparison

Compare OSPN & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneSpan Inc.

OSPN

OneSpan Inc.

N/A

Current Price

$10.63

Market Cap

390.0M

Sector

Technology

ML Signal

N/A

Logo Altimmune Inc.

ALT

Altimmune Inc.

N/A

Current Price

$3.26

Market Cap

415.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OSPN
ALT
Founded
1991
1997
Country
United States
United States
Employees
341
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
390.0M
415.3M
IPO Year
2000
2005

Fundamental Metrics

Financial Performance
Metric
OSPN
ALT
Price
$10.63
$3.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$16.67
$17.67
AVG Volume (30 Days)
602.4K
2.9M
Earning Date
04-30-2026
03-05-2026
Dividend Yield
5.00%
N/A
EPS Growth
28.77
25.37
EPS
1.88
N/A
Revenue
$243,180,000.00
$41,000.00
Revenue This Year
$3.22
N/A
Revenue Next Year
$3.16
N/A
P/E Ratio
$5.54
N/A
Revenue Growth
N/A
105.00
52 Week Low
$10.13
$2.91
52 Week High
$18.13
$7.73

Technical Indicators

Market Signals
Indicator
OSPN
ALT
Relative Strength Index (RSI) 46.40 32.85
Support Level $10.26 $2.91
Resistance Level $11.68 $4.25
Average True Range (ATR) 0.33 0.23
MACD 0.04 -0.02
Stochastic Oscillator 62.07 3.65

Price Performance

Historical Comparison
OSPN
ALT

About OSPN OneSpan Inc.

OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. The company build secure, seamless, and trusted digital experiences through two solution portfolios: Cybersecurity solutions engaged in protecting identities, securing mobile apps, and safeguarding access through high-assurance authentication, threat intelligence, fraud prevention, and robust mobile app protection, defending users, devices, and applications against sophisticated attacks, while Digital agreement solutions focuses on streamlining workflows with secure e-signatures, identity verification, and smart digital forms, built to enable speed, compliance and other customer experiences.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: